开发和部署固体口服安二乙剂型,用于治疗儿科患者群体内的内脏性莱什曼病
1Department of Urologic Sciences, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
PLoS neglected tropical diseases
|September 26, 2024
概括
开发一个口服配方的安福特乙是治疗儿童内脏莱什曼病 (VL) 的关键. 这种方法旨在克服与当前静脉注射治疗相关的挑战,改善资源有限的儿童群体的可访问性.
科学领域:
- 被忽视的热带疾病被忽视的热带疾病
- 寄生虫学的寄生虫学
- 药物开发 药物开发
背景情况:
- 内脏莱什曼病 (VL) 是一种严重的,致命的寄生虫感染,主要影响东非贫困人口.
- 目前的一线治疗,脂质体安二乙,是静脉注射,在可访问性,稳定性和成本方面提出了挑战,特别是对于儿科患者.
- 口服的米尔特福辛是一种潜在的辅助疗法,面临着可用性和副作用的问题,导致停止治疗.
研究的目的:
- 讨论开发一种新的,固体口服配方的机会和挑战.
- 解决对有VL的儿童,特别是农村地区,具有成本效益,安全和热带稳定的治疗方法的需求.
- 通过克服当前注射疗法的局限性,改善儿科VL患者的治疗坚持和治疗结果.
主要方法:
- 这一观点讨论了开发口服安二B配方的潜力.
- 它探讨了与儿科使用的配方,稳定性和输送相关的挑战.
- 它考虑了广泛实施的经济和可访问性因素.
主要成果:
- 目前静脉注射的脂质体安波特素B面临着有效的儿科VL治疗的重大障碍.
- 口服安福特里辛B配方是一个有前途的解决方案,以提高可访问性和可用性.
- 解决配方,稳定性和成本是成功开发的关键.
结论:
- 固体口服安福特里辛B配方是克服目前治疗儿科内脏莱什曼病治疗的局限性的必要条件.
- 成功开发将大大提高对资源有限的东非环境的治疗可访问性和遵守性.
- 需要进一步的研究和开发,以创建一个安全,稳定,和成本效益的口服配方为儿童.
更多相关视频
12:22A Parasite Rescue and Transformation Assay for Antileishmanial Screening Against Intracellular Leishmania donovani Amastigotes in THP1 Human Acute Monocytic Leukemia Cell Line
Published on: December 30, 2012
22.4K
12:02An Efficient Method for the Synthesis of Peptoids with Mixed Lysine-type/Arginine-type Monomers and Evaluation of Their Anti-leishmanial Activity
Published on: November 2, 2016
12.1K
相关概念视频
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:30Leishmaniasis
Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...
01:15Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...